RNS Number : 5474V RUA Life Sciences PLC 03 February 2025 3 February 2025 RUA Life Sciences Plc ("RUA Life Sciences", the "Company" or the "Group") Acquisition Update RUA Life Sciences (AIM: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon™), updates on the financial performance of its French subsidiary (ABISS) which was acquired in September 2024. ABISS has a December financial year end and, as noted in RUA's interim statements, ABISS was impacted by supply chain challenges in the nine months to September 2024. These challenges were overcome post-acquisition resulting in trading income being weighted heavily towards the final quarter of the year to 31 December 2024. The management accounts of ABISS covering the year to December have now been prepared and reviewed. At 31 December, shareholders' funds (net asset value) amounted to €1.6 million.  Total revenues of €2.3 million were achieved, representing growth of 7% over the year to December 2023.  A profit before tax of €46k was recorded compared to a loss of €352k in the prior year, and after adding back depreciation charges, EBITDA increased 147% from €185k to €457k. Due to the supply chain challenges, the pretax loss of ABISS for the 9 months to September amounted to around €450k however as, stated above, this was remedied with the result that the final quarter generated a profit of approximately €500k. Budgets and business planning are currently being undertaken with expectations for further revenue growth driven by increasing demand in Europe for ABISS's Cyrene product range. Bill Brown, CEO of RUA Life Sciences, stated: "Abiss is demonstrating itself to be a very high-quality business, and the combination with RUA allows a number of strategic opportunities to be pursued in further developing the group." The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014. For further information contact: About RUA Life Sciences The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology. Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-EonTM, manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision. Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications. The Group's four business units are: This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ACQDFLFXEFLEBBF